ABSTRACT
Objective@#To investigate the clinicopathological features, treatment and prognosis of oralmucosal malignant melanoma to provide a reference for clinical practice.@*Methods@#Data from 19 patients with oralmucosal malignant melanoma were collected, and their clinical manifestations, treatment methods and follow-up results were retrospectively analyzed. @*Results@#Among the 19 patients, 11 cases (58%) had lesions in the gingiva, 7 cases (37%) had lesions in the palate, and 1 case (5%) had lesions in the tongue, the difference was statistically significant (P<0.05). Eight patients had regional lymph node metastasis with a metastasis rate of 42%, of which 4 cases had multiple site metastasis, and the total number of regional lymph node metastasis sites was 15. Among the 19 patients, 3 cases received only surgery, 4 cases received cryotherapy, and 12 cases received combined surgery, cryotherapy and biological immunotherapy. Pathological examination showed malignant melanoma. The positive rates of S-100, HMB-45 and Melan-A were 95%, 89% and 84%, respectively. Kaplan-Meier survival analysis showed that patients with lesions less than 5 cm2 had a higher survival rate (P < 0.05).@*Conclusions@# Oral malignant melanomas usually present as black lesions in the oral mucosa, which are prone to metastasis in early stage. The area of lesions may affect the prognosis of the disease. Therefore, the large range of black lesions or masses should be the alert for the clinicians. Oral malignant melanoma patients are usually treated with combined treatment with surgery, cryotherapy and biological immunotherapy.
ABSTRACT
@#[Abstract] Objective: To observe the clinical effect of adoptive immunocyte infusion combined with immunodeprivation in the treatment of castration-resistant prostate cancer. Methods: The information of 35 patients with castration resistant prostate cancer, who were treated in the Affiliated Guizhou Provincial Cancer Hospital of Guizhou Medical University from 2011 to 2018 was collected. According to different treatments, these patients were divided into biotherapy group (18 cases) and non-biotherapy group (17 cases). Patients in the non-biotherapy group were treated with abiraterone or docetaxel, while the patients in biotherapy group were treated with cytotoxic T lymphocytes (CTL) in combination with cyclophosphamide (CTX). The treatment efficacy in the biotherapy group and the non-biotherapy group was evaluated by comparing the changes of prostate cancer-specific antigen (PSA), improvement of subjective indicators (bone pain, sleep, physical strength) and clinical efficacy before and after treatment. Results: (1) PSA level: after treatment, PSA was decreased in both groups; the biotherapy group had an obvious decrease (P<0.01),which was more significant than the decrease in non-biotherapy group (P<0.05). (2) Clinical efficacy: The clinical efficacy of patients after CTL treatment was significantly different from that of non-biotherapy group (P<0.01). (3) Subjective indicators: The bone pain, sleep and physical strength of the patients in the biotherapy group were significantly improved after treatment, and there was a significant difference as compared with patients of the non-biological treatment group (P<0.01). (4) Overall survival: The median survival of the patients receiving biotherapy was 4 months longer than patients from non-biological treatment group, but the difference was insignificant (P=0.3935). Conclusion: CTL combined with CTX in the treatment of castration resistant prostate cancer can significantly reduce PSA and improve the quality of life of patients.
ABSTRACT
Objective To investigate one year survival rate and life quality of patients with non-small cell lung cancer(NSCLC)treated by different arms.Methods One hundred and seventy-nine cases NSCLC patients from January 2013 to December 2014 were selected from the Third Hospital of Tanshan and followed-up,including 57 cases with surgical treatment,70 cases with the use of Navelbine plus cisplatin,52 cases with dendritic cells(DC)and cytokine induced killer cells(CIK)immune based therapy(DC/CIK)treatment.After one year period of radiotherapy and chemotherapy,the SF-36 questionnaire was used to investigate the quality of life of the surviving patients,and the quality of life was assessed from three aspects of the physiological,psychological and social functions.To quantify the quality of life score,the 100 percentage grading system was adopted,logistic regression analysis was used to adjust the influence of age and gender on survival rate,and the data were analyzed by SAS 9.2 statistical software package.Results One hundred and seventy-nine subjects were included in this study,by the end of follow-up on December 2015,there were 119 cases survived,the survival rate was 66.5％(119/179).Survival rate of surgical operation group,DC/CIK group and chemotherapy group orderly decreased(82.5％(47/57),76.9％(40/52)and 45.7％(32/70),P＜0.01).After adjusting age and gender impact,multiple logistic regression model showed that DC/CIK group survival rate was 3.96 times higher than the pure chemotherapy group(95％CI=1.78-8.80),surgical operation group was 5.58 times higher than simple chemotherapy group(95％CI=2.44-12.79).There were no significant differences between DC/CIK group and surgical operation group on physical disease,health status,emotional intelligence,mental health and social function,no significant difference(P＞0.05),but the chemotherapy group was lower(P＜0.05);physiological function in the chemotherapy group,operation group and DC/CIK group showed an increasing trend(P＜0.05).Conclusion The one year survival rate of NSCLC patients treated by different arms is 66.5％,and the life quality of patients with biological immune therapy method is better.
ABSTRACT
Chronic hepatitis B is a worldwide infectious diseases caused by hepatitis B virus (HBV) .HBV infection is an important reason for liver cirrhosis and liver cancer in our country .Currently ,the interferon and nucleoside analogs antiviral drugs (nucleotides) is widely used in clinical practice .These drugs inhibit the replication of the virus and disease development to a certain extent ,but not fundamentally eliminate the virus .Various therapeutic vaccines have also made certain curative effect in anti HBV ,but the effect is not perfect clinically .At present ,many research results demonstrate that biological immu-notherapy can successfully eliminate HBV virus in the body , therefore it has brought a new hope for the treatment of hepatitis B .